Effectiveness of Treatment of Bronchial Asthma With Leukotriene Receptor Antagonists in Patients by Analyzing their Quality of Life

Abstract

Bronchial asthma is a chronic disease of the bronchopulmonary system, manifested by attacks of bronchospasm and hypersecretion of mucus, in response to non-infectious inflammation of the bronchial tissues. According to the data for 2020, from 42% to 65% of patients with bronchial asthma out of the total number of patients with allergic diseases applied to the Republican Allergological Center. With insufficient effectiveness of treatment, patients may experience a restriction of daily activity, and with a prolonged course of the disease, it can lead to a fatal outcome. Therefore, improving the quality of life of patients with bronchial asthma is a priority in the treatment of this pathology.